This page does not provide medical advice
Here is a timeline of sermorelins regulatory status over the years [5]: 1990: Intravenous sermorelin was FDA approved as a GH stimulation test for the diagnosis of growth hormone deficiency (GHD)
In 2012, a Phase I randomized, double-blind, placebo-controlled, comprehensive study was conducted in Canada to evaluate the safety, tolerability, and pharmacokinetics of single and multiple escalating oral doses of GIC-1001, as well as the impact of food on the pharmacokinetics of a single oral dose of GIC-1001 in healthy subjects
The lethal dose threshold (LD1) was never achieved in animal safety studies meaning researchers could not identify a dose lethal to 1% of test subjects
Drug Interactions: Peptides may interact with certain medications
5.3 If you choose to link to our website in breach of Paragraph 5.2 you shall fully indemnify us for any loss or damage suffered as a result of your actions